This report is an updated version of the report published on 08 August 2025 at 08:06 AM GMT+ 1

PureTech Health PLC (LSE: PRTC) listed on FTSE All-Share index is a clinical stage biotherapeutics company focused on developing innovative medicines that aim to transform the lives of patients suffering severe diseases. 

Key Investment Rationale – Speculative Buy at GBX 133.40

• Clinical Progress and Pipeline Advancements: PureTech Health demonstrated meaningful progress across its clinical programs in 2024. The Phase 2b trial for deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis (IPF) met its primary and secondary endpoints, showing potential to stabilize lung function decline—a notable outcome in a disease with limited treatment options. Additionally, LYT-200, being developed by Gallop Oncology, showed promising early efficacy in acute myeloid leukemia (AML) and solid tumors, supported by Fast Track and Orphan Drug designations from the FDA.

• Strategic Monetization and Financial Discipline: The FDA approval of Cobenfy™ (KarXT) for schizophrenia, invented by PureTech and advanced by Karuna (now part of Bristol Myers Squibb), highlights the company’s ability to translate scientific innovation into commercial success. The USD 1.1 bn generated from an initial USD 18.5 mn investment underscores the financial efficiency of PureTech’s hub-and-spoke model, which balances capital allocation with value creation.

• Capital Efficiency and Favorable Balance Sheet: PureTech ended 2024 with USD 366.8 mn as of December 31, 2024, in cash and short-term investments, providing operational runway into at least 2027. The company’s disciplined approach to funding—including external capital raises for Seaport Therapeutics (USD 325.0 mn) and strategic discussions for LYT-100’s Phase 3 trial—reflects a focus on minimizing dilution while advancing key programs.

• Diversified Business Model with Founded Entities: The success of PureTech’s Founded Entities, such as Seaport Therapeutics and Vedanta Biosciences, validates its strategy of leveraging external funding and partnerships. Seaport’s rapid financing rounds and Vedanta’s Phase 3 progression for VE303 in recurrent C. difficile infection demonstrate the scalability of PureTech’s innovation engine.

PRTC Daily Chart & Valuation

One Year Technical Price Chart (as of August 07, 2025). Source: REFINITIV, Analysis: Kalkine Group

For conducting the valuation, the following peers have been considered: 4Basebio PLC (LSE: 4BB), SkinBio Therapeutics PLC (LSE: SBTX), etc.

As per the above-mentioned price action and technical indicators analysis, a ‘Speculative Buy’ rating has been given on PureTech Health PLC (LSE: PRTC) at the Closing Market Price of GBX 133.40, as of August 07, 2025.

Markets are trading in a highly volatile zone currently due to certain Macro & Micro-economic data and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is 07 August 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level which the stock is expected to reach as per the relative valuation method and/or technical analysis taking into consideration both short-term and long-term scenario.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’

Note 6: Dividend Yield may vary as per the stock price movement.